Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
REGENERON PHARMACEUTICALS, INC.
Bear Case (25th pct.)
-24.6% vs price
Base Case (Median)
-0.5% vs price
Bull Case (75th pct.)
15.3% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $884.46 | 20.1% | High (40%) |
| PE Comparable | $906.71 | 23.1% | Medium (25%) |
| Growth Trajectory DCF | $814.33 | 10.6% | Medium (20%) |
| Graham Number | $525.59 | -28.6% | Medium (40%) |
| EV/EBITDA | $567.39 | -23.0% | Medium (20%) |
| EV/FCF | $733.01 | -0.5% | Medium (20%) |
| Earnings Power Value | $543.03 | -26.3% | Medium (50%) |
Based on 7 out of 7 methods, REGN appears fairly valued at the current price of $736.50. The base case fair value of $733.01 implies 0.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.